Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis - Trial NCT06225843
Access comprehensive clinical trial information for NCT06225843 through Pure Global AI's free database. This Phase 2 trial is sponsored by Alethia Biotherapeutics and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 17 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Alethia Biotherapeutics
Timeline & Enrollment
Phase 2
Feb 15, 2024
Jun 01, 2025
Primary Outcome
Rubbia-Brandt score at surgery,Treatment-Emergent Adverse Events
Summary
This Phase II study will recruit 17 colorectal cancer patients with liver-dominant
 metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly
 for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles followed by liver
 metastases resection surgery with or without primary cancer resection. One cycle of treatment
 will consist of 14 days (2 weeks).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06225843
Non-Device Trial